Results 31 to 40 of about 5,184 (154)

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Exploration of Nirmatrelvir Derivatives as Optimized SARS‐CoV‐2 Antivirals

ChemMedChem, Volume 21, Issue 15, 14 August 2026.
Structure‐guided optimization of nirmatrelvir identifies aldehyde and dichloroacetamide warheads and a potency‐enhancing S4 thioamide. Crystal structures reveal an S2 rearrangement extending toward Cys44, suggesting a new covalent‐design opportunity.
Yugendar R. Alugubelli, Veerabhadra R. Vulupala, Kai S. Yang, Kaustav Khatua, Lauren R. Blankenship, Sathish Kumar, Demonta Coleman, Xuejiao Guo, Zhi Zachery Geng, Chia‐Chuan D. Cho, Banumathi Sankaran, Benjamin W. Neuman, Shiqing Xu, Wenshe Ray Liu   +13 more
wiley   +1 more source

Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series

Communications Medicine
Background Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection.
Alison K. Cohen, Toni Wall Jaudon, Eric M. Schurman, Lisa Kava, Julia Moore Vogel, Julia Haas-Godsil, Daniel Lewis, Samantha Crausman, Kate Leslie, Siobhan Christine Bligh, Gillian Lizars, JD Davids, Saniya Sran, Michael Peluso, Lisa McCorkell   +14 more
doaj   +1 more source

B‐Cell Depletion Relative to Tumor Necrosis Factor Inhibition Extends the Duration of Viral Shedding in COVID‐19 Among Autoimmune Disease Patients: A Matched Prospective Cohort Study

ACR Open Rheumatology, Volume 8, Issue 8, August 2026.
Objective To investigate SARS‐CoV‐2 viral shedding duration in autoimmune patients using B cell depleting (BCD) therapy or tumor necrosis factor inhibitors (TNFi) and immunocompetent comparators. Methods We conducted a matched cohort analysis among participants in POSITIVES, a prospective study enrolling outpatients with acute COVID‐19 within five days
Liya Sisay Getachew, Xiaosong Wang, Naomi J. Patel, Zachary S. Wallace, Lauren A. O'Keeffe, Madison Negron, Jiaqi Wang, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, Natalie Davis, Yijia Li, Brooke M. Leeman, Manish C. Choudhary, Sebastien Haneuse, Luke Benz, Julie Boucau, Gregory E. Edelstein, Owen T. Glover, Yumeko Kawano, Rinki Deo, Zahra Reynolds, Karry Su, Chase B. Mandell, Zoie Smith‐Sparks, Eliza Passell, Mamadou Oury Barry, Dessie Tien, Sarah P. Hammond, Gaurav D. Gaiha, Jacob E. Lemieux, Amy K. Barczak, Jonathan Z. Li, Mark J. Siedner, Jeffrey A. Sparks   +34 more
wiley   +1 more source

From prediction to intervention: Paradigm shifts in causal AI for precision medicine and large‐scale cohorts

VIEW, Volume 7, Issue 4, August 2026.
Large‐scale cohorts and multimodal biomedical data have enabled powerful predictive models for clinical risk stratification, but prediction alone cannot guide effective interventions. This review introduces causal artificial intelligence as a design‐first framework that integrates target trial emulation, causal discovery, and robust effect estimation ...
Linlin Cao, Yudian Xu, Yifan Chen, Honghao Huang, Wei Xu, Jun Pu   +5 more
wiley   +1 more source

A retrospective cohort study of prescribing outcomes in outpatients treated with nirmatrelvir-Ritonavir for COVID-19 in an interdisciplinary community clinic.

PLoS ONE, 2023
BackgroundLarge observational studies have demonstrated the real-world effectiveness of nirmatrelvir-ritonavir in preventing severe COVID-19 in higher risk individuals, but have provided limited information on other aspects of nirmatrelvir-ritonavir use.
Valerie Leung, Suzanne Gill, Andrea Llanes, Armughan Khawaja, Amanda Stagg, Janine McCready, Mariana Jacubovich, Grace Ho, Jeff Powis, Christopher Kandel   +9 more
doaj   +1 more source

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19

The Lancet Regional Health. Western Pacific, 2023
Summary: Background: Real-world data is currently limited on the association between oral antiviral therapy and healthcare system burden in patients with mild-to-moderate COVID-19.
Abraham Ka-Chung Wai, Crystal Ying Chan, Annie Wai-Ling Cheung, Kailu Wang, Sunny Ching-Long Chan, Teddy Tai-Loy Lee, Luke Yik-Fung Luk, Edmond Tsz-Fung Yip, Joshua Wing-Kei Ho, Omar Wai-Kiu Tsui, Kelly Wing-Yin Cheung, Shiyeow Lee, Chak-kwan Tong, Tafu Yamamoto, Timothy Hudson Rainer, Eliza Lai-Yi Wong   +15 more
doaj   +1 more source

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2390-2402, July 2026.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source